Image Credit: CCO
Cairn Surgical Inc., a leading creative medical technology company, actively participates in making breast cancer surgery more accurate, informed that the multicentre study publicly published in the November issue of the Annals of Surgical Oncology elaborated that the firm’s breast cancer locator (BCL) system has successfully met its initial endpoint, allowing breast surgeons to progressively eliminate the full tumor involving the negative margins in patients covering 94%. The negative margins specify no proven source of cancer in the margins of the extracted tissue.
The BCL system is engineered to enhance the precision level of breast-conserving surgery (lumpectomy) by delivering accurate guidance based on tumour size, location and shape. The precise information involves the details that other methods or traditional wire localisation do not avail. This information is planned to allow surgeons to gain enhanced cosmetic outcomes and succeed in achieving clear margins by lessening the amount of normal breast tissue eliminated.
The chief of gynaecology and clinical investigator in the study and gynecologic cancer at Agaplesion Markus Krankenhaus, Frankfurt, Germany, Prof. Dr. med. Marc Thill said, “The key goals of breast conserving surgery are to excise the cancer with optimal cosmetic result and with negative margins. In this study, the BCL system allowed surgeons to accelerate their performance with accurate breast-conserving surgery, with margin-negative extraction found in the vast majority of cases. They also accomplished low-extracted specimen volumes with stimulated patient satisfaction. The investigators see this system as a seamless symbol. They specifically applauded the visualizer tool that enables proactively viewing the tumour in 3D format and in the spine position before and during the surgery.”
The study involved 33 patients going through breast-conserving surgery to discard non-palpable breast cancer by nine surgeons at five centres in Switzerland, Italy and Germany. Most of the patients were suffering from infiltrating ductal cancers, among which 9% had ductal carcinoma in situ and 21% had infiltrating lobular cancers. The study outcomes highlighted that around 31 out of 33 patients had margin-negative extraction; one patient with DCIS and one patient showed positive margins along with invasive lobular cancer.
The co-founder of Cairn Surgical and Jr. MD, Dartmouth, Richard Barth, said, “This novel idea delivers superior and excellent detail to the surgeons about a patient's breast tumour. This holds the ability to enhance the outcomes of the breast conserving surgery.”
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
